Calendario›TCRX›TSC-204-A0201
TSC-204-A0201
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Ensayo de TScan Therapeutics, Inc. en Head and Neck Cancer · Cervical Cancer · Non-small Cell Carcinoma · Melanoma · Ovarian Cancer · Anogenital Cancers · HPV - Anogenital Human Papilloma Virus Infection · HPV-Related Cervical Carcinoma · HPV-Related Carcinoma · HPV-Related Squamous Cell Carcinoma · HPV-Related Malignancy · HPV-Related Adenocarcinoma · HPV Positive Oropharyngeal Squamous Cell Carcinoma · HPV-Related Adenosquamous Carcinoma · HPV-Associated Vaginal Adenocarcinoma · HPV-Related Endocervical Adenocarcinoma · HPV-Related Anal Squamous Cell Carcinoma · HPV-Related Verrucous Carcinoma · HPV-Related Penile Squamous Cell Carcinoma · HPV-Related Vulvar Squamous Cell Carcinoma · HPV Positive Rectal Squamous Cell Carcinoma (del registro, en inglés).
Más ensayos de: Cáncer de cabeza y cuello · Cáncer de cuello de útero · Melanoma · Cáncer de ovario.
- Fase
- Fase 1
- Estado
- En marcha, sin reclutar
- Participantes
- 840
- Centros
- 21
- Fin del objetivo primario
- dic 2026
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en may 2024.
Qué mide
Evaluate the safety of monotherapy and T- Plex combination TCR-Ts (del registro, en inglés) (28 dias)
Cómo lo describe el promotor
En el documentoEn inglés, del registroTScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.
Más ensayos de TCRX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | no aplica | En marcha, sin reclutar | ene 2026 (prevista, ya pasada: sin actualizar en el registro) |
| SOC + TSC-101 | Fase 1 | Reclutando pacientes | jun 2026 (real) |
| TSC-101 · ALLOHA-2 | Fase 3 | Reclutando pacientes | jun 2029 (prevista) |
| LTFU | no aplica | Reclutando pacientes | sep 2040 (prevista) |
| A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease | no aplica | Completado | sep 2026 (real) |
| A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. | no aplica | Completado | dic 2024 (real) |
Todos los de TCRX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05973487), actualizada en nov 2025.